688189 南新制药
已收盘 06-10 09:30:00
资讯
新帖
简况
南新制药:公司本次涉及信息披露违法违规行为不触及《上海证券交易所科创板股票上市规则》规定的重大违法强制退市情形
证券之星 · 16:09
南新制药:公司本次涉及信息披露违法违规行为不触及《上海证券交易所科创板股票上市规则》规定的重大违法强制退市情形
南新制药(688189.SH)被实施其他风险警示 6月10日停牌1天
智通财经 · 06-09 19:18
南新制药(688189.SH)被实施其他风险警示 6月10日停牌1天
每周股票复盘:南新制药(688189)转让应收款5175.67万元
证券之星 · 06-07
每周股票复盘:南新制药(688189)转让应收款5175.67万元
每周股票复盘:南新制药(688189)拟注销157万股减少注册资本
证券之星 · 05-24
每周股票复盘:南新制药(688189)拟注销157万股减少注册资本
南新制药(688189)披露2025年年度股东会决议公告,5月22日股价上涨4.39%
证券之星 · 05-22
南新制药(688189)披露2025年年度股东会决议公告,5月22日股价上涨4.39%
南新制药(688189.SH):控股股东医发投集团筹划战略重组
智通财经 · 05-14
南新制药(688189.SH):控股股东医发投集团筹划战略重组
5月11日南新制药(688189)龙虎榜数据:机构净买入2528.45万元
证券之星 · 05-11
5月11日南新制药(688189)龙虎榜数据:机构净买入2528.45万元
今日南新制药(688189)涨停分析:创新药进展、财务优化与控股股东支持驱动
证券之星 · 05-11
今日南新制药(688189)涨停分析:创新药进展、财务优化与控股股东支持驱动
股市必读:南新制药年报 - 第四季度单季净利润同比增长76.40%
证券之星 · 05-06
股市必读:南新制药年报 - 第四季度单季净利润同比增长76.40%
每周股票复盘:南新制药(688189)未弥补亏损达股本三分之一
证券之星 · 05-02
每周股票复盘:南新制药(688189)未弥补亏损达股本三分之一
图解南新制药一季报:第一季度单季净利润同比下降64.96%
证券之星 · 04-30
图解南新制药一季报:第一季度单季净利润同比下降64.96%
每周股票复盘:南新制药(688189)应收账款转让成交价5,175.67万元
证券之星 · 04-19
每周股票复盘:南新制药(688189)应收账款转让成交价5,175.67万元
南新制药(688189)披露公开挂牌转让部分应收账款进展公告,4月15日股价上涨2.79%
证券之星 · 04-15
南新制药(688189)披露公开挂牌转让部分应收账款进展公告,4月15日股价上涨2.79%
每周股票复盘:南新制药(688189)累计回购228.8万股
证券之星 · 04-05
每周股票复盘:南新制药(688189)累计回购228.8万股
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,4月2日股价上涨2.63%
证券之星 · 04-02
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,4月2日股价上涨2.63%
一年狂卖8亿元的流感创新药“失宠”,拿4.8亿元并购却惨遭打脸,南新制药扭亏困局何解?
华夏时报网 · 03-11
一年狂卖8亿元的流感创新药“失宠”,拿4.8亿元并购却惨遭打脸,南新制药扭亏困局何解?
每周股票复盘:南新制药(688189)回购股份211.8万股
证券之星 · 03-08
每周股票复盘:南新制药(688189)回购股份211.8万股
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,3月2日股价下跌5.06%
证券之星 · 03-02
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,3月2日股价下跌5.06%
每周股票复盘:南新制药(688189)2025年净亏1.372亿元
证券之星 · 03-01
每周股票复盘:南新制药(688189)2025年净亏1.372亿元
南新制药发布2025年度业绩快报,亏损1.372亿元
证券之星 · 02-27
南新制药发布2025年度业绩快报,亏损1.372亿元
加载更多
公司概况
公司名称:
湖南南新制药股份有限公司
所属行业:
医药制造业
上市日期:
2020-03-26
主营业务:
湖南南新制药股份有限公司的主营业务是抗感染、呼吸系统和心脑血管等疾病领域药品的研发、生产与销售。公司的主要产品是帕拉米韦氯化钠注射液、磷酸奥司他韦干混悬剂、辛伐他汀分散片、阿托伐他汀钙片、贝那普利氢氯噻嗪片、头孢呋辛酯分散片、头孢克洛胶囊、头孢克洛干混悬剂、乳酸环丙沙星氯化钠注射液、布洛芬混悬滴剂、布洛芬混悬液、盐酸美金刚缓释胶囊。报告期内,公司新增获得发明专利5项;截至2025年12月31日,公司累计获得授权发明专利27项,累计获得授权软件著作权4项。
发行价格:
34.94
{"stockData":{"symbol":"688189","market":"SH","secType":"STK","nameCN":"南新制药","latestPrice":7.48,"timestamp":1781054940000,"preClose":7.48,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":274000000,"shares":274000000,"eps":-0.518,"marketStatus":"已收盘","change":0,"latestTime":"06-10 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.518,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781141400000},"marketStatusCode":5,"adr":0,"adjPreClose":7.48,"symbolType":"stock_kcb","openAndCloseTimeList":[[1781055000000,1781062200000],[1781067600000,1781074800000]],"highLimit":8.23,"lowLimit":6.73,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":274400000,"isCdr":false,"pbRate":2.68,"roa":"--","roe":"--","epsLYR":-0.4989,"committee":0,"marketValue":2053000000,"turnoverRate":0,"status":2,"afterMarket":{"amount":0,"volume":0,"close":7.48,"buyVolume":0,"sellVolume":0,"time":1781076838866,"indexStatus":"已收盘 06-10 15:30:00","preClose":7.48},"floatMarketCap":2053000000},"requestUrl":"/m/hq/s/688189","defaultTab":"news","newsList":[{"id":"2642446448","title":"南新制药:公司本次涉及信息披露违法违规行为不触及《上海证券交易所科创板股票上市规则》规定的重大违法强制退市情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2642446448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642446448?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:09","pubTimestamp":1781078958,"startTime":"0","endTime":"0","summary":"证券之星消息,南新制药(688189)06月10日在投资者关系平台上答复投资者关心的问题。投资者提问:公司被ST了,会不会导致公司退市呢?南新制药回复:尊敬的投资者,您好!公司本次涉及信息披露违法违规行为不触及《上海证券交易所科创板股票上市规则》规定的重大违法强制退市情形,仅触及实施其他风险警示的情形。截至本公告披露日,公司各项生产经营活动正常有序开展。公司将严格按照相关法律法规的要求,及时履行后续进展情况的信息披露义务。感谢您的关注和支持!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000026926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462831","title":"南新制药(688189.SH)被实施其他风险警示 6月10日停牌1天","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642462831?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:18","pubTimestamp":1781003933,"startTime":"0","endTime":"0","summary":"智通财经APP讯,南新制药(688189.SH)发布公告,因公司于2026年6月9日收到中国证券监督管理委员会湖南监管局出具的《行政处罚事先告知书》(〔2026〕6号), 依据《行政处罚事先告知书》载明的内容,根据《上海证券交易所科创板股票上市规则》相关规定,公司股票将被实施其他风险警示。根据《上海证券交易所科创板股票上市规则》第12.9.1条、第12.9.2条等相关规定,公司股票将于2026年6月10日停牌1天,2026年6月11日起复牌,自复牌之日起实施其他风险警示。实施后A股简称为ST南新。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127461","title":"每周股票复盘:南新制药(688189)转让应收款5175.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127461?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:51","pubTimestamp":1780771870,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘,南新制药报收于7.74元,较上周的8.23元下跌5.95%。本周,南新制药6月1日盘中最高价报8.52元。本周关注点公司公告汇总:转让部分应收账款5,175.67万元,已收2,911.78万元。标的资产转让价款为5,175.67万元,构成关联交易,不构成重大资产重组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637442376","title":"每周股票复盘:南新制药(688189)拟注销157万股减少注册资本","url":"https://stock-news.laohu8.com/highlight/detail?id=2637442376","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637442376?lang=zh_cn&edition=full","pubTime":"2026-05-24 05:09","pubTimestamp":1779570553,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘,南新制药报收于9.74元,较上周的10.09元下跌3.47%。本周,南新制药5月18日盘中最高价报10.43元。本周关注点公司公告汇总:南新制药拟将1,570,586股回购股份注销,注册资本相应减少。本次注销后,公司总股本将由274,400,000股减少至272,829,414股,注册资本相应减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637489973","title":"南新制药(688189)披露2025年年度股东会决议公告,5月22日股价上涨4.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637489973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637489973?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:42","pubTimestamp":1779460936,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘,南新制药报收于9.74元,较前一交易日上涨4.39%,最新总市值为26.73亿元。该股当日开盘9.33元,最高9.83元,最低9.33元,成交额达9323.59万元,换手率为3.54%。近日,湖南南新制药股份有限公司披露《2025年年度股东会决议公告》。所有议案均获通过,其中特别决议议案已获三分之二以上表决权通过。控股股东对关联交易议案回避表决。会议程序合法合规,律师出具了见证意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200045496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635714203","title":"南新制药(688189.SH):控股股东医发投集团筹划战略重组","url":"https://stock-news.laohu8.com/highlight/detail?id=2635714203","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635714203?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:49","pubTimestamp":1778759367,"startTime":"0","endTime":"0","summary":"智通财经APP讯,南新制药(688189.SH)公告,公司于2026年5月14日收到公司控股股东湖南医药发展投资集团有限公司(“医发投集团”)通知,获悉医发投集团正在筹划战略重组事宜,重组方案尚未确定。截止目前,上述事项不涉及公司控股股东发生变更,不涉及公司重大资产重组事项,不涉及公司实际控制人变更,亦不会对公司的正常生产经营活动产生重大影响。此外,公司处于中国证券监督管理委员会(“中国证监会”)立案调查期间,目前尚未收到中国证监会就上述立案调查事项的结论性意见或决定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688189","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634745404","title":"5月11日南新制药(688189)龙虎榜数据:机构净买入2528.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634745404","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634745404?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:32","pubTimestamp":1778491927,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年5月11日公布的交易公开信息显示,南新制药因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年5月11日收盘,南新制药报收于10.55元,上涨20.02%,涨停,换手率12.31%,成交量33.78万手,成交额3.39亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入2528.45万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100024322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634405166","title":"今日南新制药(688189)涨停分析:创新药进展、财务优化与控股股东支持驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2634405166","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634405166?lang=zh_cn&edition=full","pubTime":"2026-05-11 15:40","pubTimestamp":1778485203,"startTime":"0","endTime":"0","summary":"证券之星消息,南新制药5月11日涨停收盘,收盘价10.55元。该股于13点9分涨停,未打开涨停,截止收盘封单资金为4415.7万元,占其流通市值1.53%。5月11日的资金流向数据方面,主力资金净流入6460.46万元,占总成交额19.05%,游资资金净流出3079.1万元,占总成交额9.08%,散户资金净流出3381.37万元,占总成交额9.97%。近5日资金流向一览见下表:该股为流感,创新药,医药概念热股,当日流感概念上涨1.95%,创新药概念上涨1.85%,医药概念上涨1.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100015781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","06978","688189","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633280809","title":"股市必读:南新制药年报 - 第四季度单季净利润同比增长76.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633280809","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633280809?lang=zh_cn&edition=full","pubTime":"2026-05-06 02:59","pubTimestamp":1778007547,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,南新制药报收于8.95元,上涨11.46%,换手率13.49%,成交量37.01万手,成交额3.33亿元。业绩披露要点财务报告南新制药2025年年报显示,当年度公司主营收入1.42亿元,同比下降43.62%;归母净利润-1.37亿元,同比上升60.49%;扣非净利润-1.38亿元,同比上升60.26%。2025年第四季度单季度主营收入5877.31万元,同比上升9520.13%;单季度归母净利润-6826.66万元,同比上升76.4%;单季度扣非净利润-7184.75万元,同比上升75.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600000912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642311","title":"每周股票复盘:南新制药(688189)未弥补亏损达股本三分之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642311","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632642311?lang=zh_cn&edition=full","pubTime":"2026-05-02 03:37","pubTimestamp":1777664228,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,南新制药报收于8.95元,较上周的7.47元上涨19.81%。本周,南新制药4月30日盘中最高价报9.58元。来自公司公告汇总:公司未弥补亏损达股本总额三分之一,拟通过优化产品结构等措施应对。股本股东变化股东户数变动截至2026年3月31日,南新制药股东户数为1.27万户,较2025年12月31日减少344.0户,减幅2.64%。注销后总股本将由274,400,000股减少至272,829,414股,注册资本相应减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631529976","title":"图解南新制药一季报:第一季度单季净利润同比下降64.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631529976","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631529976?lang=zh_cn&edition=full","pubTime":"2026-04-30 04:30","pubTimestamp":1777494636,"startTime":"0","endTime":"0","summary":"证券之星消息,南新制药2026年一季报显示,一季度公司主营收入2604.88万元,同比下降35.88%;归母净利润-1324.36万元,同比下降64.96%;扣非净利润-1345.23万元,同比下降62.3%;负债率11.72%,财务费用-15.46万元,毛利率25.21%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000012173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628335751","title":"每周股票复盘:南新制药(688189)应收账款转让成交价5,175.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628335751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628335751?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:31","pubTimestamp":1776540666,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,南新制药报收于7.53元,较上周的7.71元下跌2.33%。本周,南新制药4月15日盘中最高价报7.82元。本周关注点公司公告汇总:南新制药应收账款第三轮挂牌以5,175.67万元成交,受让方为湖南医药发展投资集团有限公司。公司公告汇总关于公开挂牌转让部分应收账款的进展公告2026年2月11日,南新制药召开董事会审议通过公开挂牌转让子公司部分应收账款的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627233817","title":"南新制药(688189)披露公开挂牌转让部分应收账款进展公告,4月15日股价上涨2.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627233817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627233817?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:24","pubTimestamp":1776263053,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘,南新制药报收于7.74元,较前一交易日上涨2.79%,最新总市值为21.24亿元。近日,南新制药披露《关于公开挂牌转让部分应收账款的进展公告》。截至公告日,双方尚未签署正式交易协议。本次交易构成关联交易,后续将履行相关审议程序并及时披露进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500043198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619873","title":"每周股票复盘:南新制药(688189)累计回购228.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619873?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:46","pubTimestamp":1775328370,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,南新制药报收于7.68元,较上周的7.69元下跌0.13%。本周,南新制药4月2日盘中最高价报8.53元。本周关注点公司公告汇总:截至2026年3月31日,南新制药累计回购股份2,288,014股,占总股本的0.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624550714","title":"南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,4月2日股价上涨2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624550714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624550714?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:29","pubTimestamp":1775140156,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘,南新制药报收于8.19元,较前一交易日上涨2.63%,最新总市值为22.47亿元。南新制药于2026年4月2日发布《关于以集中竞价交易方式回购公司股份的进展公告》。公告显示,公司于2025年4月28日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购金额为1,000万元至2,000万元,用于员工持股计划或股权激励,回购价格不超过9.53元/股,实施期限为2025年4月28日至2026年4月27日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200042627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618443489","title":"一年狂卖8亿元的流感创新药“失宠”,拿4.8亿元并购却惨遭打脸,南新制药扭亏困局何解?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618443489","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618443489?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:26","pubTimestamp":1773228360,"startTime":"0","endTime":"0","summary":" 作为曾凭抗流感创新药成名的科创板药企,南新制药(维权)近日披露2025年度业绩快报。截至2025年4月,国内帕拉米韦注射液相关批文为32个,涉及多家知名药企,直接挤压了南新制药的市场空间。 并购折戟的同时,南新制药的资金压力持续凸显。 不仅如此,因涉嫌年报信息披露违法违规,南新制药于2025年9月30日收到中国证监会《立案告知书》,目前调查仍在进行中。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-11/doc-inhqrmmk2505340.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-11/doc-inhqrmmk2505340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","BK0239","688189","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663695","title":"每周股票复盘:南新制药(688189)回购股份211.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663695","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663695?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:18","pubTimestamp":1772911092,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,南新制药报收于8.15元,较上周的8.5元下跌4.12%。本周,南新制药3月2日盘中最高价报8.44元。本周关注点公司公告汇总:截至2026年2月28日,公司累计回购股份2,118,214股,占公司总股本的0.77%。截至2026年2月28日,公司累计回购股份2,118,214股,占公司总股本的0.77%,已支付资金总额17,918,614.54元,回购价格区间为7.02元/股至8.92元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616359504","title":"南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,3月2日股价下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616359504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616359504?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:33","pubTimestamp":1772465591,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,南新制药报收于8.07元,较前一交易日下跌5.06%,最新总市值为22.14亿元。近日,湖南南新制药股份有限公司披露《关于以集中竞价交易方式回购公司股份的进展公告》。公告显示,公司于2025年4月28日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购资金总额不低于1,000万元且不超过2,000万元,回购价格不超过9.53元/股,回购期限为12个月,自2025年4月28日至2026年4月27日,拟用于员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616845423","title":"每周股票复盘:南新制药(688189)2025年净亏1.372亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616845423","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616845423?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:59","pubTimestamp":1772305148,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,南新制药报收于8.5元,较上周的8.48元上涨0.24%。本周,南新制药2月25日盘中最高价报8.75元。本周关注点来自业绩披露要点:南新制药2025年归属净利润亏损1.372亿元,同比减亏61.54%。公司公告汇总湖南南新制药股份有限公司发布2025年度业绩快报,报告期内实现营业总收入14,192.76万元,同比下降46.09%;营业利润为-13,250.69万元,利润总额为-13,267.37万元,归属于母公司所有者的净利润为-13,724.83万元,亏损幅度较上年大幅减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614283589","title":"南新制药发布2025年度业绩快报,亏损1.372亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614283589","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614283589?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:17","pubTimestamp":1772183823,"startTime":"0","endTime":"0","summary":"证券之星消息,南新制药近日即将发布2025年年报,根据2月27日发布的业绩快报,归属净利润亏损1.372亿元,同比增长61.54%。报告期内,公司实现营业收入 14,192.76 万元,比上年同期减少 46.09%;实现营业利润-13,250.69 万元,实现利润总额-13,267.37万元,实现归属于母公司所有者的净利润-13,724.83 万元。报告期内,受国内医药行业集中采购等政策深入推进、同类竞品不断上市等因素影响,市场竞争加剧,加之 2025 年前三季度国内流感较少,导致公司营业收入和毛利率均有所下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700028481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781098176665,"stockEarnings":[{"period":"1week","weight":-0.0496},{"period":"1month","weight":-0.149},{"period":"3month","weight":-0.0811},{"period":"6month","weight":-0.1127},{"period":"1year","weight":-0.0765},{"period":"ytd","weight":-0.0615}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0407},{"period":"3month","weight":-0.0299},{"period":"6month","weight":0.0353},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南南新制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12673人(较上一季度减少2.64%)","perCapita":"21652股","listingDate":"2020-03-26","address":"湖南省长沙市浏阳市经济技术开发区康里路1号","registeredCapital":"27440万元","survey":" 湖南南新制药股份有限公司的主营业务是抗感染、呼吸系统和心脑血管等疾病领域药品的研发、生产与销售。公司的主要产品是帕拉米韦氯化钠注射液、磷酸奥司他韦干混悬剂、辛伐他汀分散片、阿托伐他汀钙片、贝那普利氢氯噻嗪片、头孢呋辛酯分散片、头孢克洛胶囊、头孢克洛干混悬剂、乳酸环丙沙星氯化钠注射液、布洛芬混悬滴剂、布洛芬混悬液、盐酸美金刚缓释胶囊。报告期内,公司新增获得发明专利5项;截至2025年12月31日,公司累计获得授权发明专利27项,累计获得授权软件著作权4项。","listedPrice":34.94},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"南新制药(688189)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供南新制药(688189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"南新制药,688189,南新制药股票,南新制药股票老虎,南新制药股票老虎国际,南新制药行情,南新制药股票行情,南新制药股价,南新制药股市,南新制药股票价格,南新制药股票交易,南新制药股票购买,南新制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"南新制药(688189)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供南新制药(688189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}